surpass-cvot tirzepatide Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics Post hoc analysis of SURPASS-CVOT

Peptides 171:171149

2021-2023: SURMOUNT Weight Management Program Four Phase 3 trials specifically evaluated weight reduction in participants without diabetes [3] : SURMOUNT-1: Pivotal 72-week trial (n=2,539) showing up to 22.5% total body weight loss with 15 mg dosethe highest weight loss ever reported for a pharmacological obesity intervention SURMOUNT-2: Obesity trial in participants with type 2 diabetes achieving 15.7% weight loss [5] SURMOUNT-3: Withdrawal study demonstrating 6.7% weight regain in placebo group vs

The dual-receptor activation in tirzepatide appears to produce stronger metabolic suppression in many patients

This is not a complete list of risks